Regencell Bioscience Holdings LTD RGC
We take great care to ensure that the data presented and summarized in this overview for Regencell Bioscience Holdings Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RGC
View all-
Geode Capital Management, LLC Boston, MA391KShares$5.26 Million0.0% of portfolio
-
Y Intercept (Hong Kong) LTD13KShares$175,2840.01% of portfolio
-
Greenfield Savings Bank11KShares$147,8400.09% of portfolio
-
Royal Bank Of Canada Toronto, A6948Shares$12,7410.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY698Shares$9,3810.0% of portfolio
-
Black Rock Inc. New York, NY238Shares$3,1980.0% of portfolio
-
Citigroup Inc70Shares$9400.0% of portfolio
-
Farther Finance Advisors, LLC San Francisco, CA50Shares$6720.0% of portfolio
-
Morgan Stanley New York, NY5Shares$670.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$0100.0% of portfolio
Latest Institutional Activity in RGC
Top Purchases
Top Sells
About RGC
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Insider Transactions at RGC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|